TransCode Therapeutics’ (RNAZ) Buy Rating Reiterated at HC Wainwright

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $3.00 price target on the stock.

TransCode Therapeutics Stock Performance

TransCode Therapeutics stock opened at $0.34 on Friday. TransCode Therapeutics has a 1 year low of $0.22 and a 1 year high of $18.66. The firm’s 50 day moving average price is $0.49 and its two-hundred day moving average price is $0.69.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). Equities research analysts forecast that TransCode Therapeutics will post -2.06 earnings per share for the current year.

Hedge Funds Weigh In On TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC bought a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.